Inovio Pharmaceuticals Inc vs Liberty Global Ltd Class C — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Liberty Global Ltd Class C trades at $10.08 (market cap $3.47B). The key difference: Liberty Global Ltd Class C is far larger — about 38.9× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| INO | LBTYK | |
|---|---|---|
Market Cap | $89.27M | $3.47B |
Sector | Health | Technology |
52-Week High | $2.87 | $12.67 |
52-Week Low | $1.05 | $10.00 |
Enterprise Value | $60.28M | $10.75B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LBTYK trades at $9.995, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights strategic moves, including the planned 2027 Amsterdam listing of Ziggo Group. Analyst consensus is strongly positive, with 69% recommending Buy.
The outlook hinges on execution of the Ziggo Group spin-off, a potential value catalyst. However, persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. The stock offers a deep value opportunity if management delivers on restructuring, but operational turnaround is critical for sustained recovery.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →